Comprehensive molecular characterization of mitochondrial genomes in human cancers.

Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H, PCAWG Consortium. · 2020

Read Comprehensive molecular characterization of mitochondrial genomes in human cancers. by Yuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H, PCAWG Consortium. (2020) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7058535.txt.

Introduction

Yuan and co-authors characterise mitochondrial genomes in human cancers in Nature Genetics. Mitochondria are the cell's power plants and matter greatly in cancer, yet their small genomes are often skipped by sequencing studies. Within the pan-cancer whole-genome consortium, the team combined mitochondrial genome data with matching RNA data across thousands of tumours.

The analysis covers 2,658 cancers across 38 tumour types and presents the most definitive landscape of mitochondrial mutations so far, including several hypermutated cases. Truncating mutations were markedly enriched in kidney, colorectal, and thyroid cancers, suggesting they can help drive those diseases. The team also found frequent transfers of mitochondrial DNA into the nuclear genome, some disrupting genes targeted by therapy. Mitochondrial copy number varied widely and tracked with clinical variables. Co-expression patterns connect mitochondrial genes to energy production, DNA repair, and the cell cycle, laying groundwork for clinical uses.

Catalog record

CREATORYuan Y, Ju YS, Kim Y, Li J, Wang Y, Yoon CJ, Yang Y, Martincorena I, Creighton CJ, Weinstein JN, Xu Y, Han L, Kim HL, Nakagawa H, Park K, Campbell PJ, Liang H, PCAWG Consortium.
YEAR2020
COLLECTIONPAPERS
FORMATTXT
FILE SIZE89 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7058535

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Comprehensive molecular characterization of mitochondrial genomes in human cancers By Yuan Yuan, Young Seok Ju, Youngwook Kim, Jun Li, Yumeng Wang, Christopher J Yoon, Yang Yang, Inigo Martincorena, Chad J Creighton, John N Weinstein, Yanxun Xu, Leng Han Published in: Nature Genetics DOI: 10.1038/s41588-019-0557-x ABSTRACT Abstract Mitochondria are essential cellular organelles that play critical roles in cancer. Here, as part of the International Cancer Genome Consortium/The Cancer Genome Atlas Pan-Cancer Analysis of Whole Genomes Consortium, which aggregated whole-genome sequencing data from 2,658 cancers across 38 tumor types, we performed a multidimensional, integrated characterization of mitochondrial genomes and related RNA sequencing data. Our analysis presents the most definitive mutational landscape of mitochondrial genomes and identifies several hypermutated cases. Truncating mutations are markedly enriched in kidney, colorectal and thyroid cancers, suggesting oncogenic effects with the activation of signaling pathways. We find frequent somatic nuclear transfers of mitochondrial DNA, some of which disrupt therapeutic target genes. Mitochondrial copy number varies greatly within and across cancers and correlates with clinical variables. Co-expression analysis highlights the function of mitochondrial genes in oxidative phosphorylation, DNA repair and the cell cycle, and shows their connections with clinically actionable genes. Our study lays a foundation for translating mitochondrial biology into clinical applications. Subject terms: Cancer, Genomics MAIN Mitochondria are crucial cellular organelles in eukaryotes, and there can be several hundred mitochondria in a single human cell1. Known as ‘the powerhouses of the cell’, mitochondria play essential roles in generating most of the cell’s energy through oxidative phosphorylation2. Despite its small size (16.6 kilobases (kb)), the circular mitochondrial genome encodes 13 proteins that form respiratory chain complexes with other proteins of nuclear origin3. The involvement of mitochondria in carcinogenesis has long been suspected4,5 because altered energy metabolism is a common feature of cancer6. Furthermore, mitochondria play important roles in other tasks, such as biosynthesis, signaling, cellular differentiation, apoptosis, maintaining control of the cell cycle and cell growth, all of which are intrinsically linked to tumorigenesis5,7. In several recent studies, molecular characterization of mitochondria was performed in cancer by using next-generation sequencing data8–13, but these studies usually describe one specific dimension of the mitochondrial genome (for example, somatic mutations) based on relatively small sample cohorts. Furthermore, due to the whole-exome sequencing data employed, the relatively low depth of mitochondrial genomes limits the accuracy and scope of these studies. Thus, a comprehensive, multidimensional molecular portrait of mitochondria across a broad range of cancer types has not been achieved. Moreover, previous studies have focused on the patterns of mitochondrial alterations alone, without fully exploring the interplay between the mitochondrial genome and the nuclear genome, as well as the biomedical significance of mitochondrial alterations. The Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium aggregated whole-genome sequencing (WGS) data from 2,658 cancers across 38 tumor types generated by the International Cancer Genome Consortium (ICGC) and The Cancer Genome Atlas (TCGA) projects. These sequencing data were re-analyzed with standardized, high-accuracy pipelines to align to the human genome (reference build hs37d5) and identify germline variants and somatically acquired mutations, as described14. Meanwhile, TCGA has generated RNA sequencing (RNA-seq) data from a large number of patient samples, which allow for assessment of the transcriptional activities of mitochondrial genes15. These large-scale datasets create a tremendous resource for characterizing cancer mitochondrial genomes at an unprecedented level (Fig. 1a). We first characterized mitochondrial somatic mutations, nuclear transfers and copy numbers, then investigated their interactions with nuclear somatic alterations16,17, and finally examined the expression profiles of mitochondrial genes and their connections with clinically relevant nuclear genes. [Figure: Mutational landscape and process of cancer mitochondrial genomes.a, Overview of our multidimensional and integrated mitochondrial genome analyses. b, Landscape of mtDNA somatic substitutions. The numbers represent the mitochondrial genome coordinates. The outer (blue) circle shows the density of all variants with VAF > 1%. The inner (red) circle shows the density of variants with VAF > 3%. c, Highly consistent mtDNA mutational spectrum across 21 cancer tissue groups. Average numbers of somatic substitutions per sample are also shown (right). d, Correlation between the highest VAF of mtDNA mutations in a cancer tissue and patient age at the time of diagnosis. The correlation was based on the 2,414 patients with both age and somatic single-nucleotide variant information available. The shaded region represents the 95% confidence interval for the predictions from a linear model with the highest VAF as the response variable and patient age as the explanatory variable. e, Correlations between the numbers of nuclear and mtDNA somatic mutations. The associations were tested among samples with both nuclear and mtDNA somatic mutations available (with sample sizes labeled on plot) using Spearman’s rank correlation. Magenta bars indicate significant positive correlations (P < 0.05). Asterisks indicate that both nuclear and mitochondrial somatic mutations were correlated with patient age in that cancer type (P < 0.05). f, Proportions of tumor samples harboring different categories of somatic alterations: nuclear driver alterations only (red); both nuclear driver alterations and mtDNA mutations (VAF > 10%, green); and mtDNA mutations without known nuclear drivers (blue). AML, acute myeloid leukemia; BNHL, B cell non-Hodgkin lymphoma; CA, carcinoma; ChRCC, chromophobe renal cell carcinoma; CLL, chronic lymphocytic leukemia; CNS, central nervous system; eso, esophageal; GBM, glioblastoma; HCC, hepatocellular carcinoma; leiomyo, leiomyosarcoma; liposarc, liposarcoma; medullo, medulloblastoma; MPN, myeloproliferative neoplasm; oligo, oligometastatic; osteosarc, osteosarcoma; PiloAstro, pilocytic astrocytoma; RCC, renal cell carcinoma; SCC, squamous cell carcinoma; TCC, transitional cell carcinoma; adenoCA, adenocarcinoma; epith, epithelioid.] RESULTS Mutational landscape of cancer mitochondrial genomes To characterize somatic mutations in mitochondrial genomes across cancer types, we extracted the mitochondrial DNA (mtDNA) mapped reads of 2,658 cancer and matched control sample pairs from the PCAWG Consortium. The samples we surveyed covered 21 cancer tissues and 38 specific cancer types (Supplementary Table 1). On average, the sequencing depth for the mitochondrial genome was 9,959×, which was much higher than that obtained from whole-exome sequencing data, allowing for confident detection of somatic mutations at a very low heteroplasmic level (variant allele fraction (VAF) > 1%; Supplementary Fig. 1). By applying a well-designed computational pipeline that carefully considered various potentially confounding factors (for example, sample cross-contamination, mismapping of reads from nuclear mtDNA-like sequence18, and artifactual mutations caused by oxidative DNA damage during library preparation19), we identified a total of 7,611 somatic substitutions and 930 small indels in 2,536 high-quality cancer samples (122 samples were excluded in the mutation analysis for the issues mentioned above; Supplementary Fig. 2 and Methods). The high reliability of the mutations was confirmed by long-range PCR-based validation (Supplementary Table 2) and by inspection of the mutational spectrum of the very low-VAF mutation candidates (Supplementary Fig. 3). Of the 7,611 substitutions, >85% were clearly heteroplasmic, showing VAFs lower than 0.6 (average: 0.2; median: 0.045). Overall, mtDNA mutations located in the transcribed regions were also found in RNA-seq with similar VAFs, except for a fraction of transfer RNA (tRNA) mutations showing much higher VAFs in transcripts due to the accumulation of unprocessed tRNA precursors during the processing of polycistronic mitochondrial transcripts10 (Supplementary Fig. 4). Across all of the cancer samples, we observed several mutational hotspots in the regulatory D-loop region and the ND4 gene (Fig. 1b). Of the 13 protein-coding genes, ND5 was the most frequently mutated in most cancer types, while ND4 was most

Read the complete text